Advances in the relationship between AP-1 and tumorigenesis, development and therapy resistance

被引:0
|
作者
Xue, Xinni [1 ]
Li, Zhiwei [1 ]
Zhao, Jiahui [2 ]
Zhao, Ziyi [2 ]
Li, Zhihang [2 ]
Li, Yong [2 ]
Liu, Yawen [2 ]
He, Huan [1 ]
机构
[1] Jilin Univ, Sch Publ Hlth, NHC Key Lab Radiobiol, Changchun 130021, Jilin, Peoples R China
[2] Jilin Univ, Sch Publ Hlth, Dept Epidemiol & Biostat, Changchun 130021, Jilin, Peoples R China
关键词
AP-1; Tumors; Tumorigenesis; Drug resistance; Radiation resistance; BREAST-CANCER; C-FOS; CELL-PROLIFERATION; TRANSCRIPTION; INHIBITION; EXPRESSION; RECEPTORS; GENE; JUN; RADIOSENSITIVITY;
D O I
10.1007/s12672-025-01783-1
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
Activating protein 1 (AP-1) is a transcription factor composed of several protein families, Jun proteins and Fos proteins are the components of AP-1. AP-1 is involved in various cellular processes, such as proliferation, differentiation, apoptosis and inflammation. For tumor cells, AP-1 is considered to be a driver whose activity is associated with dysfunction and the onset, development, invasion, and migration of cancer. In addition, AP-1 has been reported to be involved in the drug resistance and radiation resistance of tumor cells during the treatment process. Therefore, AP-1 is a potential target for cancer therapy. At present, a number of inhibitors targeting AP-1 have been developed and have shown certain anti-cancer effects. However, due to the complex structure and function of AP-1, different structures of AP-1 show different effects in different tumor cells, and more studies are needed to reveal its mechanism of action. This article introduces the relationship between AP-1 and tumor development, summarize the current studies and developments of AP-1 related drugs, and provide the future development values of AP-1.
引用
收藏
页数:15
相关论文
共 50 条
  • [1] AP-1 in mouse development and tumorigenesis
    Wolfram Jochum
    Emmanuelle Passegué
    Erwin F Wagner
    Oncogene, 2001, 20 : 2401 - 2412
  • [2] AP-1 in mouse development and tumorigenesis
    Jochum, W
    Passegué, E
    Wagner, EF
    ONCOGENE, 2001, 20 (19) : 2401 - 2412
  • [3] Blockade of AP-1 Potentiates Endocrine Therapy and Overcomes Resistance
    Malorni, Luca
    Giuliano, Mario
    Migliaccio, Ilenia
    Wang, Tao
    Creighton, Chad J.
    Lupien, Mathieu
    Fu, Xiaoyong
    Hilsenbeck, Susan G.
    Healy, Nuala
    De Angelis, Carmine
    Mazumdar, Abhijit
    Trivedi, Meghana V.
    Massarweh, Suleiman
    Gutierrez, Carolina
    De Placido, Sabino
    Jeselsohn, Rinath
    Brown, Myles
    Brown, Powel H.
    Osborne, C. Kent
    Schiff, Rachel
    MOLECULAR CANCER RESEARCH, 2016, 14 (05) : 470 - 481
  • [4] AP-1: A double-edged sword in tumorigenesis
    Eferl, R
    Wagner, EF
    NATURE REVIEWS CANCER, 2003, 3 (11) : 859 - 868
  • [5] AP-1: a double-edged sword in tumorigenesis
    Robert Eferl
    Erwin F. Wagner
    Nature Reviews Cancer, 2003, 3 : 859 - 868
  • [6] The role of AP-1 in glucocorticoid resistance in leukaemia
    S Bailey
    AG Hall
    ADJ Pearson
    CPF Redfern
    Leukemia, 2001, 15 : 391 - 397
  • [7] The role of AP-1 in glucocorticoid resistance in leukaemia
    Bailey, S
    Hall, AG
    Pearson, ADJ
    Redfern, CPF
    LEUKEMIA, 2001, 15 (03) : 391 - 397
  • [8] Glucocorticoid resistance and the Ap-1 transcription factor in leukaemia
    Bailey, S
    Hall, AG
    Pearson, ADJP
    Reid, HM
    DRUG RESISTANCE IN LEUKEMIA AND LYMPHOMA III, 1999, 457 : 615 - 619
  • [9] AP-1 transcriptional activity determines keratinocyte lineage commitment during tumorigenesis
    Gerdes, MJ
    Frost, NA
    Levy, MR
    Moitra, J
    Glick, AB
    Vinson, C
    Yuspa, SH
    JOURNAL OF INVESTIGATIVE DERMATOLOGY, 2004, 122 (03) : A22 - A22
  • [10] Deciphering AP-1 function in tumorigenesis - Fra-ternizing on target promoters
    Verde, Pasquale
    Casalino, Laura
    Talotta, Francesco
    Yaniv, Moshe
    Weitzman, Jonathan B.
    CELL CYCLE, 2007, 6 (21) : 2633 - 2639